Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab for Guillain-Barré Syndrome
NCT05494619Phase 3Withdrawn
- Sponsor
- Roche
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of crovalimab in Guillain-Barré syndrome (GBS), sponsored by Roche. Planned start Nov 2022; status: withdrawn.
02
Drugs
crovalimab
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on NCT05494619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05494619.